How High-Quality PK Reports Accelerate Your IND Filing

In new drug development, successfully completing nonclinical pharmacokinetics (PK) studies is a major milestone on the path to an Investigational New Drug (IND) application. But completing the studies is only half the battle — delivering a high-quality report that meets the rigorous standards of global regulatory agencies is what truly determines whether your submission moves forward without delay.

At WuXi AppTec DMPK, we do not just meet the bar; we set it. With a comprehensive quality management system, standardized workflows, deep technical expertise across modalities and platforms, and increasing automation, we aim to help clients produce submission-ready PK reports that support efficient IND filings worldwide.

Quality First: Keeping Submissions on Track

At WuXi AppTec DMPK, quality isn't a checkbox. It's the foundation. We have built an end-to-end quality management system designed to help ensure that data and reports can stand up to scrutiny from global regulatory agencies.

• Standardized SOPs Across Every Step

  From study design and sample processing to data analysis and report writing, every stage is executed under rigorously defined Standard Operating Procedures (SOPs). This means clear handoffs, controlled processes, and accurate, reproducible data every single time.

• Data Integrity and Traceability

  We enforce strict data integrity controls through electronic audit trails and dual reviewer verification processes. Our robust document management system creates a complete, traceable chain from raw experimental records all the way through to the final regulatory submission report, so you are always audit-ready.

• One Study, Global Submission

  Our DMPK reports are prepared to align with eCTD (electronic Common Technical Document) expectations and can support submissions to major agencies, including the FDA, EMA, PMDA, and NMPA—supporting the goal of “one study, global submission,” and helping reduce avoidable rework and timeline risk.

Expertise That Scales with Complexity

As novel drug modalities and development strategies evolve, PK programs and reporting requirements are becoming more complex. We continue to expand our capabilities to match these needs.

• A Proven Track Record

  Our reporting team has supported more than 1,700 successful IND filings. Team members hold professional certifications in industry-standard software platforms, including Phoenix WinNonlin, and bring hands-on experience that translates directly into submission-ready reports.

• Coverage Across Emerging Modalities

  Beyond conventional small molecules, we have established analytical and reporting capabilities across today's most exciting therapeutic frontiers. We expertly handle PROTACs (proteolysis targeting chimeras), oligonucleotides, antibody-based therapeutics, peptides, recombinant fusion proteins, mRNA therapeutics, and biomarkers.

• Multiplatform Technical Support

  We provide expert data interpretation and reporting support across a broad range of detection and delivery platforms. This includes analytical platforms like LC-MS/MS, MSD, ELISA, and qPCR, as well as specialized therapeutic area platforms for CNS, ophthalmology, and transdermal drug delivery.

• Multisite Coordination, Unified Standards

  Leveraging our intelligent collaborative platform, our teams across New Jersey, Shanghai, Suzhou, Nanjing, and Nantong work in seamless coordination. This guarantees consistent report formatting and standardized quality, regardless of which site handles your program.

Quality Meets Efficiency: Our Automation Revolution

Raising the quality bar and accelerating turnaround are not mutually exclusive. Through continuous technology innovation, we have proven you can have both.

From "Chasing Data" to "Data Finds You"

We have eliminated the inefficiencies of manual workflows and repetitive data handling. By developing proprietary automation tools and building a structured electronic lab notebook (ELN) system, we have achieved end-to-end automation spanning data collection, analysis, and report generation. Today, our reporting automation robots handle the entire workflow, from study information entry and PK parameter calculation to final report export, taking efficiency to a new level.

Triple Layer Quality Control

We have established a 3-tier quality assurance framework that catches errors at every level:

• Automated Precheck: System-level validation for data consistency

• Expert Manual Review: Comprehensive review by our scientific team to verify data accuracy

• Independent QC Audit: Regular sampling audits by a dedicated quality management team to monitor overall project quality

Each layer reinforces the others, ensuring our clients consistently receive reports they can submit with confidence.

Toward Full IND Reporting Automation

To date, we have fully automated the output of IND validation reports, achieving a >50% improvement in report writing efficiency. The ongoing digitization of IND study notebooks signals that fully automated IND report generation, from study initiation to submission-ready output, is well within reach.

Making Every Report a Source of Confidence in Your Filing

In an era where the speed of drug development is accelerating, speed and quality are no longer a tradeoff. They are a shared imperative. At WuXi AppTec DMPK, quality is our foundation. Expertise is our engine. Automation is what gives us wings. We do not just provide a technical service. We are a committed partner alongside our clients on every step of the IND submission journey, from the first experiment to the day your application is accepted.

Talk to a WuXi AppTec expert today to get the support you need to achieve your drug development goals.

Committed to accelerating drug discovery and development, we offer a full range of discovery screening, preclinical development, clinical drug metabolism, and pharmacokinetic (DMPK) platforms and services. With research facilities in the United States (New Jersey) and China (Shanghai, Suzhou, Nanjing, and Nantong), 1,000+ scientists, and over fifteen years of experience in Investigational New Drug (IND) application, our DMPK team at WuXi AppTec are serving 1,600+ global clients, and have successfully supported 1,700+ IND applications.